HEALTH

Ducere Pharma names Pete Rose Myoflex spokesman

BY Michael Johnsen

PHILADELPHIA — Pete Rose, baseball’s all-time hits leader, is the new spokesperson for the topical muscle, joint and arthritis pain reliever Myoflex, Ducere Pharma announced recently. 
 
“Pete’s a Hall of Famer in our eyes and we are excited to have him on board with Myoflex,” stated Chris Dominello, Ducere Pharma CEO. “He is a legendary player who is known across all generations. The passion and intensity that Pete brought to the game of baseball has inspired many kids of his and future generations to give 110% no matter what they are doing. Pete played the game like no other and Myoflex is a pain reliever like no other.”
 
Rose, also known during his playing days as “Charlie Hustle” because of the reckless abandon he played the game with, will make appearances, appear in advertising and be available for media tours as part of his agreement with Myoflex.
 
“I suffer from a number of aches and pains because of the way I played baseball,” Rose said. “Since starting to use Myoflex, I can already feel a difference. Myoflex is a great product that helps soothe the aches and pains that go along with giving it your all no matter what you do. I am looking forward to working with the great people of Myoflex and Ducere Pharma.”
 
Rose is baseball’s all-time hits leader with 4,256 hits and holds a number of other records. When you combine his desire to win at all costs and his on-field success, this made him one of the most popular baseball players of his generation, Ducere noted. 
 
“When you look at what he meant for the game of baseball, his hustle, grit and determination, you can see why so many kids wanted to be like him and play like him, even as they got older and transitioned into weekend warriors,” Dominello said. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Study in Annals of the Rheumatic Diseases bears out efficacy of Cosamin DS

BY Michael Johnsen

EDGEWOOD, Md. — Nutramax Labs announced Thursday the publication of results from an international clinical study that demonstrates the effectiveness of glucosamine hydrochloride and chondroitin sulfate — the same active ingredients found in the joint health dietary supplement Cosamin DS — in the management of joint health and wellness. The results of the MOVES (Multicentre Osteoarthritis InterVEntion trial with Sysadoa) study are published in the online edition of the peer-reviewed journal, Annals of the Rheumatic Diseases.
 
“The MOVES trial is truly an important study that provides additional evidence to support the use of glucosamine hydrochloride and chondroitin sulfate, at a daily dose of 1,500 and 1,200 milligrams, respectively, in managing joint health in a wide variety of patient populations,” stated Nicholas DiNubile, clinical associate in the Department of Orthopedic Surgery at the Hospital of the University of Pennsylvania. “This new data is especially encouraging for patients, and it reinforces my ongoing approach to long-term joint health management in my practice, particularly for people who are experiencing a significant increase in the incidence of deteriorating joint health yet wish to remain physically active.”
 
Cosamin DS is the most researched glucosamine/chondroitin joint health supplement, Nutramax stated. Cosamin DS uses FCHG49 glucosamine and TRH122 chondroitin sulfate, providing a unique combination of ingredients not found in other glucosamine/chondroitin combination dietary supplements. “I tell my patients, not all supplements are created equal – brand matters. It’s important to recommend supplements supported by extensive research like Cosamin,” DiNubile said.
 
“We were the first company to develop this combination worldwide and publish clinical studies showing its benefits for joint health. We have been conducting both human and veterinary research for over 20 years, so it’s gratifying to see studies of this magnitude that confirm our previous findings. The MOVES study further underscores the value of Cosamin DS as a safe and effective option to support joint health,” said Robert Henderson, chairman Nutramax.
 
MOVES is a multicenter, randomized, parallel-group, double-blind, controlled clinical trial that enrolled 606 patients at 42 centers in France, Germany, Poland and Spain. The study was sponsored by Bioibérica, suppliers of the chondroitin sulfate used in Cosamin DS. The study was developed as an extension of the GAIT (Glucosamine/Chondroitin Arthritis Intervention Trial) study, which showed that the combination of glucosamine hydrochloride (1,500 mg/day) and chondroitin sulfate (1,200 mg/day) was effective in a moderate to severe subgroup of patients.
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

ONE Condoms taps local urban artist community to promote national HIV prevention campaign

BY Michael Johnsen

 

 
 
NEW YORK— ONE Condoms on Thursday announced the launch of a national HIV prevention campaign that features a coalition of visual artists, musicians, celebrities and public health agencies.
 
#LustforLife (onecondoms.com/lustforlife) aims to help stop the spread of HIV/AIDS in America's urban communities, where 70% of the 50,000 new HIV infections in the United States occur each year. The campaign brought together 22 graffiti and street artists who created unique works of art on full-sized STOP signs with designs promoting safer sex. The collection was curated by Billi Kid, a contemporary artist, designer and curator whose aesthetic mixes graffiti and street art sensibilities with sophisticated nods to high art, fashion and design. The campaign kicks off with a launch event for an exhibit featuring the works of art at the Urban Outfitters store in New York City's Herald Square on Friday, Feb. 6 at 6 p.m.
 
Starting with World AIDS Day (Dec. 1, 2014), the 22 designs were revealed in a social media campaign during the month of December. In partnership with Paddle8, the #LustforLife works of art will be sold in an online public auction from Feb. 6-20, in tandem with National Condom Week (Feb. 14-21, 2015), with proceeds to benefit Lifebeat, Music Fights HIV/AIDS. Lifebeat is the leading national non-profit dedicated to educating America's youth about HIV/AIDS prevention. For 22 years, Lifebeat has been on the front lines distributing safe-sex materials to millions of at-risk youth at concert venues, music festivals and clubs throughout U.S.

In the past year, Lifebeat performed outreach on many national tours including Macklemore & Ryan Lewis, Sam Smith, Mad Decent Block Party Tour, Fall Out Boy, CHVRCHES, and Romeo Santos, and major music festivals including South by Southwest, Ultra Music Festival, Electric Daisy Carnival and Electric Zoo.

 
"ONE's mission is to increase condom use by creating products and programs that make it easier to learn about, talk about and practice safer sex," stated Davin Wedel, president of Global Protection Corp., parent company of ONE. "The #LustforLife campaign sends a powerful message about the importance of safer sex to prevent the spread of HIV and AIDS in America's urban communities. We created the campaign to bring all of us — artists, health activists, community leaders and consumers — together to shine a national spotlight on this issue."
 
Wedel noted that the launch in New York will be followed by similar campaigns in other major urban communities, each with its own unique expression of unity among local artists, public figures and health organizations.
 
ONE is producing #LustforLife condom wrappers featuring eight of the STOP sign designs and will distribute millions of them through public health organizations nationwide. The company also will introduce retail 12-packs and other products showcasing the designs and will donate a portion of sales to urban outreach programs.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?